Latest & greatest articles for metformin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metformin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metformin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metformin

121. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study (Abstract)

Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study To compare the cardiovascular risks associated with second-line oral antidiabetic agents added to initial metformin therapy in a large nationwide observational study.We conducted a nationwide retrospective cohort study using the Taiwan National Health Insurance database. A total of 36 118 users of different add-on oral antidiabetic agents (...) (sulphonylureas, glinides, pioglitazone, α-glucosidase inhibitors and dipeptidyl peptidase-4 inhibitors) after initial metformin therapy were included in the analysis. The reference group was sulphonylureas added to metformin, the most commonly used combination regimen. The main outcomes of interest were hospitalizations for any cardiovascular event including acute myocardial infarction, congestive heart failure and ischaemic stroke. In the main analysis, all patients were followed within their initiation

2015 EvidenceUpdates

122. Is It Time to Reconsider Who Should Get Metformin?

Is It Time to Reconsider Who Should Get Metformin? Is It Time to Reconsider Who Should Get Metformin? – Clinical Correlations Search Is It Time to Reconsider Who Should Get Metformin? December 11, 2015 6 min read Cho YM, Kieffer TJ. New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia . 2011:54(2):219-222. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N,N-dimethylbiguanide) in man. Clin Pharmacol Ther (...) . 1978:24(6):683-693. Pernicova I, Korbonits M. Metformin—mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol . 2014:10(3):143-156. Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA . 2014:312(24):2668-2675. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med .1998:338:265-266

2015 Clinical Correlations

123. Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes (Abstract)

Durability and tolerability of dapagliflozin over 52 weeks as add-on to metformin and sulphonylurea in type 2 diabetes To evaluate the safety and efficacy of dapagliflozin as add-on therapy to metformin plus sulphonylurea over 52 weeks.Patients with type 2 diabetes mellitus (T2DM) using sulphonylurea and metformin received dapagliflozin 10 mg/day or placebo added to therapy for 52 weeks (24-week randomized, double-blind period plus 28-week double-blind extension).A total of 219 patients were (...) with dapagliflozin (15.6%) than with placebo (8.3%). Genital infections were reported in more patients in the dapagliflozin (10.1%) than in the placebo group (0.9%) and urinary tract infection frequency was similar in the two groups (10.1 and 11.0%).Dapagliflozin as add-on to metformin plus a sulphonylurea was well tolerated and improvement in glycaemic control was maintained over 52 weeks.© 2015 John Wiley & Sons Ltd.

2015 EvidenceUpdates Controlled trial quality: uncertain

124. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial Full Text available with Trip Pro

Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial To confirm the superiority, compared with placebo, of adding liraglutide to pre-existing basal insulin analogue ± metformin in adults with inadequately controlled type 2 diabetes [glycated haemoglobin (HbA1c) 7.0-10.0% (53-86 mmol/mol)].In this 26-week, double-blind, parallel-group study, conducted in clinics (...) or hospitals, 451 subjects were randomized 1 : 1 to once-daily liraglutide 1.8 mg (dose escalated from 0.6 and 1.2 mg/day, respectively, for 1 week each; n = 226) or placebo (n = 225) added to their pre-existing basal insulin analogue (≥20 U/day) ± metformin (≥1500 mg/day). After randomization, insulin adjustments above the pre-study dose were not allowed. The primary endpoint was HbA1c change.After 26 weeks, HbA1c decreased more with liraglutide [-1.3% (-14.2 mmol/mol)] than with placebo [-0.1% (-1.2 mmol

2015 EvidenceUpdates Controlled trial quality: predicted high

125. Clinical Review: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea

Clinical Review: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea | CADTH.ca Find the information you need Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin (...) and a Sulfonylurea Published on: August 16, 2010 Product Line: Therapeutic Review Result type: Report Tags diabetes mellitus, diabetes mellitus, type 2, type 2 diabetes mellitus, diabetes mellitus, type ii, metformin, sulfonylurea compounds, diabetes, Third-Line Therapy for Patients with Type 2, Diabetes Inadequately Controlled with, Metformin and a Sulfonylurea Files Therapeutic Review Recommendation Report August 2010 Therapeutic Review Economic Evaluation August 2010 Therapeutic Review Clinical Review August

2015 CADTH - Therapeutic Review

126. Economic Evaluation: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and Sulfonylurea Combination Therapy

Economic Evaluation: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and Sulfonylurea Combination Therapy Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea | CADTH.ca Find the information you need Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled (...) with Metformin and a Sulfonylurea Published on: August 16, 2010 Product Line: Therapeutic Review Result type: Report Tags diabetes mellitus, diabetes mellitus, type 2, type 2 diabetes mellitus, diabetes mellitus, type ii, metformin, sulfonylurea compounds, diabetes, Third-Line Therapy for Patients with Type 2, Diabetes Inadequately Controlled with, Metformin and a Sulfonylurea Files Therapeutic Review Recommendation Report August 2010 Therapeutic Review Economic Evaluation August 2010 Therapeutic Review

2015 CADTH - Therapeutic Review

127. Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) Full Text available with Trip Pro

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from

2015 EvidenceUpdates Controlled trial quality: uncertain

128. Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study (Abstract)

Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study To compare diabetes-associated secondary healthcare utilization in patients with type 2 diabetes (T2DM) prescribed sulphonylureas (SUs) versus other oral antihyperglycaemic agents (OHAs) as an add-on to metformin monotherapy (metformin + SU vs metformin + OHA).This retrospective (...) cohort study used data from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. Adults with T2DM initiated on metformin + SU or metformin + OHA from April 2003 to March 2012 were identified. Patients were matched using propensity scores. Diabetes-associated secondary healthcare visits were counted from >6 months post-initiation of dual therapy until treatment change or end of follow-up. Outcomes were calculated as rate ratios, adjusted for over-dispersion using negative

2015 EvidenceUpdates

129. Hypoglycaemic agents and type 2 diabetes: metformin should be the first-line drug treatment

Hypoglycaemic agents and type 2 diabetes: metformin should be the first-line drug treatment Prescrire IN ENGLISH - Spotlight ''Hypoglycaemic agents and type 2 diabetes: metformin should be the first-line drug treatment'', 1 May 2015 {1} {1} {1} | | > > > Hypoglycaemic agents and type 2 diabetes: metformin should be the first-line drug treatment Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |  (...)  |   |   |  Spotlight Hypoglycaemic agents and type 2 diabetes: metformin should be the first-line drug treatment Metformin is the only drug that appears to prevent some complications of diabetes and reduce the mortality of type 2 diabetes patients. Type 2 diabetes is a frequent disease primarily affecting adults over the age of 40. The aim of treatment is to avoid or delay the occurrence of severe, sometimes fatal complications. It relies firstly on diet and exercise

2015 Prescrire

130. A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. Full Text available with Trip Pro

A presurgical window-of-opportunity study of metformin in obesity-driven endometrial cancer. Metformin use is associated with reduced cancer risk in several observational studies of patients with type 2 diabetes. Results from preclinical studies in endometrial cancer show that metformin reduces cellular proliferation by inhibition of the PI3K-AKT-mTOR pathway. We tested the hypothesis that metformin would reduce cellular proliferation in vivo in atypical endometrial hyperplasia and endometrial (...) endometrioid adenocarcinoma.We recruited women attending gynaecological oncology clinics in Manchester, UK, with atypical endometrial hyperplasia or endometrial endometrioid adenocarcinoma. Women received metformin (850 mg twice daily) or no drug (control) during the 1-4 week presurgical window between cancer diagnosis and hysterectomy according to patient preference. Paired blood and tumour samples were obtained at recruitment and hysterectomy. Cellular proliferation was assessed by Ki-67 proliferation

2015 Lancet

131. [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)]

[Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)] Canagliflozin/metformin. Nutzenbewertung gemass Section 35a SGB V [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)] Canagliflozin/metformin. Nutzenbewertung gemass Section 35a SGB V [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)] IQWiG Record Status (...) This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation IQWiG. Canagliflozin/metformin. Nutzenbewertung gemass Section 35a SGB V. [Canagliflozin/metformin. Benefit assessment according to section 35a Social Code Book V (dossier assessment)] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 255. 2014 Final publication URL Indexing

2015 Health Technology Assessment (HTA) Database.

132. Ebymect - dapagliflozin / metformin

Ebymect - dapagliflozin / metformin 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 24 September 2015 EMA/679419/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Ebymect International non-proprietary name: dapagliflozin / metformin Procedure No. EMEA/H/C/004162/0000 Note Assessment report as adopted (...) and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control • in patients inadequately controlled on their maximally tolerated dose of metformin alone • in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products (see sections 4.4, 4.5 and 5.1 for available data on different combinations) • in patients already being treated with the combination

2015 European Medicines Agency - EPARs

133. Synjardy - empagliflozin / metformin

Synjardy - empagliflozin / metformin 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5520 Send a question via our website www.ema.europa.eu/contact 26 March 2015 EMA/238334/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Synjardy International non-proprietary name: empagliflozin / metformin Procedure No. EMEA/H/C/003770/0000 Note Assessment report as adopted (...) lipoprotein LOCF Last observation carried forward Assessment report EMA/238334/2015 Page 4/99 MDRD Modification of Diet in Renal Disease MedDRA Medical dictionary for drug regulatory activities Met Metformin MMRM Mixed model repeated measures NDA New Drug Application NCF Non-completers considered failure OC Observed cases Pio Pioglitazone PIP Paediatric Investigational Plan PT Preferred term qd Once-daily SAF Safety trial grouping SBP Systolic blood pressure SD Standard deviation SE Standard error SGLT

2015 European Medicines Agency - EPARs

134. Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin

Systematic review with meta analysis: In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our (...) or password? You are here In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Article Text Therapeutics/Prevention Systematic review with meta analysis In women with gestational diabetes requiring drug treatment, glibenclamide may be inferior to insulin and metformin: metformin (plus insulin when required) performs better than insulin Dana Carroll , Kristi W Kelley

2015 Evidence-Based Medicine

135. Metformin to reduce weight gain and metabolic disturbance in schizophrenia

Metformin to reduce weight gain and metabolic disturbance in schizophrenia Metformin to reduce weight gain and metabolic disturbance in schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts (...) Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin to reduce weight gain and metabolic disturbance in schizophrenia Article Text Pharmacological interventions Metformin to reduce weight gain and metabolic disturbance in schizophrenia Guy Faulkner , Mark Duncan Statistics from

2015 Evidence-Based Mental Health

136. Flowchart: Intrapartum management for gestational diabetes mellitus requiring Insulin and/or Metformin

Flowchart: Intrapartum management for gestational diabetes mellitus requiring Insulin and/or Metformin Document Number: F15.33--2-V1-R20 Department of Health Queensland Clinical Guidelines State of Queensland (Queensland Health) 2015 http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en Queensland Clinical Guidelines, Guidelines@health.qld.gov.au Intrapartum management for GDM requiring Insulin and/or Metformin Metformin • Cease when labour established Insulin • Cease when labour (...) established • If morning IOL (and labour not established) o Eat breakfast and give usual rapid acting Insulin o Omit morning long or intermediate acting Insulin • If afternoon IOL (and labour not established) o Give usual mealtime and bedtime Insulin GDM Insulin or Metformin Mode of birth? Day before procedure • Cease Metformin 24 hours prior to procedure • Give usual Insulin the night before procedure Day of morning procedure • Fast from 2400 hours • Omit morning Insulin Monitor BGL 2/24 > 7.0 : greater

2015 Queensland Health

137. Systematic review: Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment

Systematic review: Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metformin should not be contraindicated in patients with type 2 diabetes and mild to moderate renal impairment Article Text Aetiology/Harm Systematic

2015 Evidence-Based Medicine

138. Alogliptin/metformin (Vipdomet®)

Alogliptin/metformin (Vipdomet®) Alogliptin/metformin (Vipdomet®) Alogliptin/metformin (Vipdomet®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Alogliptin/metformin (Vipdomet®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales (...) Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 3314. 2014 Authors' conclusions Alogliptin/metformin (Vipdomet®) is recommended as an option for restricted use for dual oral therapy within NHS Wales. Alogliptin/metformin (Vipdomet®) should be restricted for use in the following circumstances within its licensed indication for the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: • As an adjunct to diet and exercise to improve glycaemic

2015 Health Technology Assessment (HTA) Database.

139. Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin Full Text available with Trip Pro

Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin This study compared the efficacy and safety of dual add-on of saxagliptin plus dapagliflozin versus saxagliptin and dapagliflozin added on alone in patients with type 2 diabetes poorly controlled with metformin.This was a double-blind trial in adults with HbA1c ≥8.0 (...) % and ≤12.0% (64-108 mmol/mol), randomized to saxagliptin (SAXA) (5 mg/day) plus dapagliflozin (DAPA) (10 mg/day; n = 179), or SAXA (5 mg/day) and placebo (n = 176), or DAPA (10 mg/day) and placebo (n = 179) on background metformin extended release (MET) ≥1,500 mg/day. Primary objective compared changes from baseline in HbA1c with SAXA+DAPA+MET versus SAXA+MET and DAPA+MET.Patients had a mean baseline HbA1c of 8.9% (74 mmol/mol), diabetes duration of 7.6 years, and a BMI of 32 kg/m(2). At week 24

2014 EvidenceUpdates Controlled trial quality: uncertain

140. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects

Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects Prescrire IN ENGLISH - Spotlight ''Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects '', 1 November 2014 {1} {1} {1} | | > > > Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects Spotlight Every month (...) , the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects FEATURED REVIEW The efficacy of metformin in type 2 diabetes is still thinly documented in 2014. However, an abundance of data is now available on its adverse effects. The evidence is relatively weak

2014 Prescrire